Causal Attribution Challenges in Single Arm Trials

135 concepts134 papers7 proposals

When evaluating a new medical treatment, digital health intervention, or educational framework, the fundamental question we seek to answer is simple: Did the intervention cause the observed outcome? To answer this definitively, we must compare what happened after the intervention to what would have happened in its exact absence—a theoretical baseline known as the counterfactual.

In a randomized controlled trial (RCT), a dedicated control group serves as a proxy for this counterfactual. However, across many research domains, executing an RCT is frequently impractical due to ethical constraints, rare patient populations, or early-phase exploratory designs. Instead, researchers often rely on single-arm or uncontrolled studies, where every participant receives the intervention. As explored by Barbara Pistilli et al. in Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial, while these single-arm designs are highly valuable for generating hypotheses and demonstrating preliminary safety, they introduce profound challenges in causal attribution. Without a concurrent control group, isolating the true therapeutic effect from external noise becomes an intricate puzzle.

The Mechanics of Confounding

Why exactly does the absence of a control group undermine causal certainty? When a single group of participants is measured before and after an intervention, several distinct mechanisms can mimic a true treatment effect, making it difficult to isolate the specific impact of the intervention.

Natural History and Spontaneous Remission

Many conditions are inherently dynamic; symptoms naturally wax and wane over time. In an observational study on psoriatic arthritis, Petros P. Sfikakis et al. note in Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study that without a placebo or active comparator arm, it is nearly impossible to distinguish drug-induced improvements from the natural history of the condition. If a disease naturally enters a period of low activity, a completely ineffective treatment can appear highly successful.

The Placebo and Hawthorne Effects

The psychological and behavioral shifts associated with participating in a study can heavily skew results. For instance, in a study evaluating a mobile application for stroke risk factors, Jaewoo Kang et al. highlight in Feasibility of Using a Mobile Application for the Monitoring and Management of Stroke-Associated Risk Factors how the Hawthorne effect—where individuals alter their behavior simply because they know they are being monitored—makes it difficult to isolate the digital tool's specific impact from routine clinical care.

Similarly, Yi Xie demonstrates in Ginkgo Biloba Extract Is Comparable With Donepezil in Improving Functional Recovery in Alzheimer’s Disease: Results From a Multilevel Characterized Study Based on Clinical Features and Resting-State Functional Magnetic Resonance Imaging that excluding a placebo group prevents researchers from separating a drug's specific pharmacological impact from the general psychological benefits of receiving increased medical attention.

Concurrent Interventions and Environmental Factors

Participants rarely exist in a vacuum during a trial. In the GLORIA trial, Daisaku Masuda et al. observe in Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial) that the lack of a placebo control group makes it difficult to disentangle a drug's direct metabolic effects from concurrent lifestyle modifications made by the patients.

This issue extends to behavioral interventions as well: Choong-Hee Park et al. point out in Effects of Forest Therapy Program on Stress levels and Mood State in Fire Fighters that a single-group pre- and post-test design cannot rule out the "vacation effect"—the inherent psychological relief of taking a break from a high-stress work environment—as the primary driver of improvement, rather than the specific forest therapy protocol itself.

The Comparative Efficacy Gap

Even when an intervention clearly drives positive outcomes, single-arm trials suffer from a second critical limitation: the inability to establish comparative efficacy. Knowing that an intervention works is fundamentally different from knowing if it works better than the current standard of care.

In oncology, early-phase trials frequently utilize single-arm designs to evaluate novel therapeutics. For example, Yuankai Shi et al. demonstrate promising objective response rates for a novel anti-PD-1 antibody in Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002) (Journal of Hematology & Oncology 2021), yet the authors acknowledge that the single-arm design prevents a direct comparison with existing standard-of-care protocols, introducing uncertainty regarding its true incremental benefit.

This sentiment is echoed by Pin Zhang et al. in A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer and María Ángeles Vaz Salgado et al. in Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial, who note that the lack of a parallel control group leaves open the question of whether observed survival or disease control rates genuinely surpass what could be achieved via traditional regimens.

This comparative gap is equally pronounced in surgical innovation. When a new surgical technique is introduced, such as the laparoscopic approach detailed by Zhewen Feng et al. in Innovative laparoscopic 'Tunnel' approach in managing hiatal hernia with gastroesophageal reflux disease: a retrospective study, the absence of a direct control group prevents a head-to-head statistical comparison against established standards. Consequently, clinicians cannot definitively determine if the technical innovation offers a statistically significant advantage in safety or long-term efficacy over traditional methods.

Recognizing that logistically or ethically constrained environments will always necessitate single-arm studies, researchers employ several strategies to mitigate the causal attribution challenge.

One common approach is the use of historical controls—comparing the results of a single-arm trial against data collected from past studies using standard treatments. As seen in a multicenter prospective study by Min Ruan et al., Homoharringtonine added to CLAG regimen improves outcome of pediatric Relapsed/Refractory AML: A multicenter prospective study, historical data can provide vital context for evaluating a new combination therapy. However, the authors emphasize that historical controls are an imperfect substitute for concurrent control arms, as changes in supportive care, patient demographics, and diagnostic criteria over time can introduce severe selection bias.

To address these limitations computationally, machine learning researchers are developing frameworks specifically designed to estimate treatment effects when control arms are missing or fragmented. In Multi-Task Adversarial Learning for Treatment Effect Estimation in Basket Trials, Zhixuan Chu et al. highlight that many traditional treatment effect models are fundamentally restricted by single-arm designs. To overcome this, the authors propose a multi-task adversarial learning framework that "borrows strength" across different parallel cohorts (or baskets) to mitigate selection bias and mathematically simulate control conditions.

Ultimately, while advanced statistical modeling and historical benchmarks help narrow the epistemic gap, the core consensus across these diverse fields remains unchanged: single-arm studies serve as powerful tools for establishing feasibility, safety, and generating hypotheses, but randomized controlled trials remain the definitive gold standard for true causal attribution.

History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_lack_of_control_group_e0f27828,
  title = {lack of control group},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/lack-of-control-group/rdr_e0f278282d2548369d262c34aac5e606},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_lack_of_control_group_e0f27828_v1,
  title = {lack of control group},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/lack-of-control-group/rdr_e0f278282d2548369d262c34aac5e606/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake